Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 20

1.

Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of n-3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure.

Tavazzi L, Tognoni G, Franzosi MG, Latini R, Maggioni AP, Marchioli R, Nicolosi GL, Porcu M; GISSI-HF Investigators.

Eur J Heart Fail. 2004 Aug;6(5):635-41.

2.

[The role of statins in the treatment of heart failure].

Eren M.

Turk Kardiyol Dern Ars. 2009 Oct;37(7):501-11. Review. Turkish.

3.

[To treat or not to treat with statins patients with chronic heart failure?].

Hradec J.

Vnitr Lek. 2009 Sep;55(9):802-7. Review. Czech.

PMID:
19785380
5.

[Ongoing trials and future prospects].

Baldasseroni S, Fabbri G, Maggioni AP.

Ital Heart J. 2003 Dec;4 Suppl 7:58S-64S. Review. Italian.

PMID:
14983747
6.

Cholesterol lowering, cardiovascular diseases, and the rosuvastatin-JUPITER controversy: a critical reappraisal.

de Lorgeril M, Salen P, Abramson J, Dodin S, Hamazaki T, Kostucki W, Okuyama H, Pavy B, Rabaeus M.

Arch Intern Med. 2010 Jun 28;170(12):1032-6. doi: 10.1001/archinternmed.2010.184. Review.

PMID:
20585068
7.

Cardiovascular risk reduction: what do recent trials with rosuvastatin tell us?

Fabbri G, Maggioni AP.

Adv Ther. 2009 May;26(5):469-87. doi: 10.1007/s12325-009-0025-6. Epub 2009 May 14. Review.

PMID:
19444394
8.

[Treatment of chronic heart failure. The time of statins?].

Mareev VIu.

Kardiologiia. 2005;45(12):4-10. Review. Russian. No abstract available.

PMID:
16353040
9.

[Cardiology 2008].

Hoppe UC, Erdmann E.

Dtsch Med Wochenschr. 2008 Jun;133(25-26):1341-3. doi: 10.1055/s-2008-1081076. Review. German. No abstract available.

PMID:
18553258
10.

Cardiovascular risk in uremic patients: darkness after AURORA.

Robles NR, Macias JF.

Ren Fail. 2010 Jan;32(2):269-72. doi: 10.3109/08860221003602652. Review. No abstract available.

PMID:
20199190
12.

Rosuvastatin and progression of atherosclerosis.

Nicholls SJ.

Expert Rev Cardiovasc Ther. 2008 Aug;6(7):925-33. doi: 10.1586/14779072.6.7.925. Review. Erratum in: Expert Rev Cardiovasc Ther. 2009 Jan;7(1):97.

PMID:
18666843
13.

Rosuvastatin: a review of its use in the management of dyslipidemia.

Scott LJ, Curran MP, Figgitt DP.

Am J Cardiovasc Drugs. 2004;4(2):117-38. Review. Erratum in: Am J Cardiovasc Drugs. 2005;5(2):130.

PMID:
15049723
14.

Rosuvastatin-associated adverse effects and drug-drug interactions in the clinical setting of dyslipidemia.

Kostapanos MS, Milionis HJ, Elisaf MS.

Am J Cardiovasc Drugs. 2010;10(1):11-28. doi: 10.2165/13168600-000000000-00000. Review.

PMID:
20104931
15.

Lipid-lowering drug therapies and chronic obstructive pulmonary disease: lung failure or just heart failure?

Wierzbicki AS, Louis R.

Int J Clin Pract. 2014 Feb;68(2):144-51. doi: 10.1111/ijcp.12329. Review. No abstract available.

PMID:
24460612
16.

[Inhibitory effect of n-3 polyunsaturated fatty acids on colorectal cancers].

Danbara N, Yuri T, Tsujita M, Senzaki H, Tsubura A.

Nihon Rinsho. 2003 Sep;61 Suppl 7:519-21. Review. Japanese. No abstract available.

PMID:
14574948
17.

Effects of supplementation with polyunsaturated fatty acids in patients with heart failure.

Nodari S, Triggiani M, Manerba A, Milesi G, Dei Cas L.

Intern Emerg Med. 2011 Oct;6 Suppl 1:37-44. doi: 10.1007/s11739-011-0671-y. Review.

PMID:
22009611
18.

[Eicosapentaenoic acid ethyl esters].

Ohtsuka S.

Nihon Rinsho. 2007 Jul 28;65 Suppl 7:489-93. Review. Japanese. No abstract available.

PMID:
17824076
19.

n-3 PUFAs and heart failure.

Marchioli R, Levantesi G.

Int J Cardiol. 2013 Dec 20;170(2 Suppl 1):S28-32. doi: 10.1016/j.ijcard.2013.06.041. Epub 2013 Sep 6. Review.

PMID:
24012159
20.

[Pharmacogenomics of statin therapy].

Li L, Xie YC, Lu GP.

Zhonghua Xin Xue Guan Bing Za Zhi. 2006 Jan;34(1):88-91. Review. Chinese. No abstract available.

PMID:
16626568

Supplemental Content

Support Center